XML 54 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
EARNINGS (LOSS) PER SHARE
 6 Months Ended
Jun. 30, 2014
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE
EARNINGS (LOSS) PER SHARE
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc. for the three-month and six-month periods ended June 30, 2014 and 2013 were calculated as follows:
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2014
 
2013
 
2014
 
2013
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.
$
125.8

 
$
10.8

 
$
103.2

 
$
(16.7
)
 
 
 
 
 
 
 
 
Basic weighted-average number of common shares outstanding
335.3

 
308.1

 
335.1

 
307.7

Diluted effect of stock options and RSUs(a)
6.0

 
6.3

 
6.3

 
—

Diluted weighted-average number of common shares outstanding
341.3

 
314.4

 
341.4

 
307.7

 
 
 
 
 
 
 
 
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
 
 
 
 
 
 
 
Basic
$
0.38

 
$
0.04

 
$
0.31

 
$
(0.05
)
Diluted
$
0.37

 
$
0.03

 
$
0.30

 
$
(0.05
)
____________________________________
(a)
In the six-month period ended June 30, 2013, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
 
 
Six Months Ended
June 30,
 
 
2013
Basic weighted-average number of common shares outstanding
 
307.7

Dilutive effect of stock options and RSUs
 
6.4

Diluted weighted-average number of common shares outstanding
 
314.1


In the three-month and six-month periods ended June 30, 2014, stock options to purchase approximately 915,000 common shares of the Company were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method, compared with approximately 14,000 and 99,000 common shares in the corresponding periods of 2013.